97 related articles for article (PubMed ID: 23697875)
1. The importance of Notch signaling in peripheral T-cell lymphomas.
Kamstrup MR; Biskup E; Gjerdrum LM; Ralfkiaer E; Niazi O; Gniadecki R
Leuk Lymphoma; 2014 Mar; 55(3):639-44. PubMed ID: 23697875
[TBL] [Abstract][Full Text] [Related]
2. Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?
Kamstrup MR; Biskup E; Gniadecki R
Br J Dermatol; 2010 Oct; 163(4):781-8. PubMed ID: 20560956
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.
van Kester MS; Tensen CP; Vermeer MH; Dijkman R; Mulder AA; Szuhai K; Willemze R; van Doorn R
J Invest Dermatol; 2010 Feb; 130(2):563-75. PubMed ID: 19710685
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
6. γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
Dorneburg C; Goß AV; Fischer M; Roels F; Barth TF; Berthold F; Kappler R; Oswald F; Siveke JT; Molenaar JJ; Debatin KM; Beltinger C
Oncotarget; 2016 Sep; 7(39):62799-62813. PubMed ID: 27588497
[TBL] [Abstract][Full Text] [Related]
7. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells.
Han B; Liu SH; Guo WD; Zhang B; Wang JP; Cao YK; Liu J
World J Gastroenterol; 2015 Sep; 21(33):9727-35. PubMed ID: 26361419
[TBL] [Abstract][Full Text] [Related]
8. Gamma-secretase inhibitors suppress the growth of leukemia and lymphoma cells.
Kogoshi H; Sato T; Koyama T; Nara N; Tohda S
Oncol Rep; 2007 Jul; 18(1):77-80. PubMed ID: 17549349
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.
Zettl A; Rüdiger T; Konrad MA; Chott A; Simonitsch-Klupp I; Sonnen R; Müller-Hermelink HK; Ott G
Am J Pathol; 2004 May; 164(5):1837-48. PubMed ID: 15111330
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.
Hu J; Zhu X; Lu Q
J Int Med Res; 2013 Aug; 41(4):1017-26. PubMed ID: 23839278
[TBL] [Abstract][Full Text] [Related]
11. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
[TBL] [Abstract][Full Text] [Related]
12. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
14. The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
Dang Q; Chen L; Xu M; You X; Zhou H; Zhang Y; Shi W
Cell Signal; 2019 Jul; 59():76-84. PubMed ID: 30878517
[TBL] [Abstract][Full Text] [Related]
15. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
Suwanjunee S; Wongchana W; Palaga T
Anticancer Drugs; 2008 Jun; 19(5):477-86. PubMed ID: 18418214
[TBL] [Abstract][Full Text] [Related]
17. MAML1 regulates cell viability via the NF-κB pathway in cervical cancer cell lines.
Kuncharin Y; Sangphech N; Kueanjinda P; Bhattarakosol P; Palaga T
Exp Cell Res; 2011 Aug; 317(13):1830-40. PubMed ID: 21640102
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
Liu S; Breit S; Danckwardt S; Muckenthaler MU; Kulozik AE
Ann Hematol; 2009 Jul; 88(7):613-21. PubMed ID: 19057901
[TBL] [Abstract][Full Text] [Related]
19. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
20. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
